The massive EPS beat and raised guidance suggest strong operational momentum. Monitor upcoming Q2 guidance and Titan XT adoption for sustained upside. The stock is likely to react positively on this earnings surprise.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $45.51entry
- T+1 · 7mo ago −5.30%α −5.29% · $43.10
- T+5 · 7mo ago −4.55%α −6.24% · $43.44
- T+20 · 6mo ago −3.10%α −8.57% · $44.10
- T+60 · 4mo ago −12.41%α −16.40% · $39.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omnicell reported strong Q1 2026 results with total revenue of $310M (+15% YoY), GAAP EPS of $0.25 (vs -$0.15), and non-GAAP EPS of $0.55 (vs $0.26). The company raised full-year 2026 non-GAAP EBITDA and EPS guidance, signaling accelerating profitability and demand for its medication management solutions.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $310M, up 15% YoY from $270M
- GAAP net income $11M ($0.25/diluted share) vs loss of $7M (-$0.15)
- Non-GAAP net income $25M ($0.55/diluted share) vs $12M ($0.26)
- Operating cash flow $55M, up from $26M YoY
- Raised FY 2026 non-GAAP EBITDA guidance to $153M-$168M (from $145M-$160M)
- Raised FY 2026 non-GAAP EPS guidance to $1.80-$2.00 (from $1.65-$1.85)
- Cash and equivalents $239M, no debt drawn on $350M revolver
Financial Impact
Revenue up 15% YoY to $310M, non-GAAP EPS $0.55 vs consensus $0.13 (implied beat), guidance raised for FY 2026
Risk Factors
- Product bookings declined 4% in FY 2025, indicating potential lumpiness
- Guidance assumes continued demand, but macro headwinds could impact hospital capital spending
- Integration of new products (Titan XT, OmniSphere) may take longer than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000926326-26-000009 |
| Document: omcl-20260428.htm | 0000926326-26-000009 |
| Document: 0000926326-26-000009-index-headers.html | 0000926326-26-000009 |
| Document: 0000926326-26-000009-index.html | 0000926326-26-000009 |
| Document: 0000926326-26-000009.txt | 0000926326-26-000009 |
| 8-K Data (Synthetic) | 0000926326-26-000009 |
Track record
11 reports on OMCL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $35.06 Now $35.44 +1.10% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $34.71 Now $35.44 +2.10% settles Feb 12
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $37.34 Now $35.44 −5.09% settles Feb 4
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $36.88 Now $35.44 −3.90% settles Jan 27
- Jul 30, 202615w ago 8-K Bullish 7/10 Entry $37.11 to $37.75 Now $35.44 −4.50% ▲ +1.72% −0.74% vs SPY
- Jul 1, 202619w ago 8-K Neutral 2/10 Entry $41.93 to $33.03 Now $35.44 −15.48% ▼ −21.23% −24.18% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 5/10 Entry $37.83 to $33.88 Now $35.44 −6.32% ▼ −10.44% −13.71% vs SPY
- May 26, 202624w ago 8-K Neutral 2/10 Entry $43.12 to $35.50 Now $35.44 −17.81% ▼ −17.67% −19.55% vs SPY
- Apr 28, 202628w ago 8-K Bullish 8/10 Viewing Entry $45.51 to $39.86 Now $35.44 −22.13% ▼ −12.41% −16.40% vs SPY
- Feb 2, 202641w ago Court Ruling Neutral 2/10 Entry $46.04 to $41.42 Now $35.44 −23.02% ▼ −10.03% −14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers